Quick Answer
TANDEM DIABETES CARE INC reported R&D Expense of $92.05 million for fiscal year 2021.
TANDEM DIABETES CARE INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2021 | $92.05M | +44.8% |
| 2020 | $63.57M | +40.7% |
| 2019 | $45.20M | +54.6% |
| 2018 | $29.23M | +41.5% |
| 2017 | $20.66M | +9.8% |
| 2016 | $18.81M | +10.9% |
| 2015 | $16.96M | +7.4% |
| 2014 | $15.79M | +42.5% |
| 2013 | $11.08M | +23.0% |
| 2012 | $9.01M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2022 | $33.57M | +63.8% | +1.2% |
| March 31, 2022 | $33.16M | +84.6% | +37.6% |
| September 30, 2021 | $24.10M | +49.8% | +17.6% |
| June 30, 2021 | $20.50M | +28.2% | +14.1% |
| March 31, 2021 | $17.96M | +27.2% | +11.6% |
| September 30, 2020 | $16.09M | +33.7% | +0.7% |
| June 30, 2020 | $15.99M | +42.7% | +13.2% |
| March 31, 2020 | $14.12M | +50.4% | +17.3% |
- TANDEM DIABETES CARE INC showed an increase of +44.8% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2021 period, TANDEM DIABETES CARE INC’s r&d expense has grown by 921.8% (from $9.01 million to $92.05 million).
- The most recent figure is from TANDEM DIABETES CARE INC’s fiscal year 2021 report (Form 10-K), filed with the SEC on February 22, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: